Balanced news tone
News Sentiment
ESLA sentiment intelligence
Estrella Immunopharma Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
46
Balanced news tone
43 relevant articles
Price is moving more forcefully than the current news tone suggests.
75/100 classification confidence.
directly relevant articles
high-authority source matches
-9.4% over one week, -11.6% over four weeks, trend inactive, and below fair value.
Enterprise value to EBIT forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
75/100 classification
One-week reaction
-9.4%
Price reacting lower
Trend fit
Trend inactive
-11.6% over four weeks
Fair value
-53.3%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
2
Neutral
32
Negative
9
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
TradingView
Direct company coverage
Enterprise value to EBIT forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW
This article provides financial information for Estrella Immunopharma, Inc. (NASDAQ:ESLAW), focusing on its enterprise value to EBIT forward metric on TradingView. It highlights that the market was closed and no trades occurred, presenting an overview of the company's financial d
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jul 2026 14:40
- Source
- TradingView
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
TradingView
Direct company coverage
Enterprise value to revenue forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW
The article focuses on the enterprise value to revenue forward metric for Estrella Immunopharma, Inc., traded on NASDAQ under the symbol ESLAW. It appears to be a financial data page from TradingView, providing an overview of the company's financial metrics. The core content is t
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 12:13
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW
The article provides information about the "Price to earnings forward" for Estrella Immunopharma, Inc. (NASDAQ: ESLAW). It notes that the market was closed with no trades. The period, value, and change for this metric are mentioned as being made by humans.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 04:03
- Source
- TradingView
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 07:00
- Source
- Market source
TradingView
Direct company coverage
Enterprise value to revenue forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA
This article provides financial information for Estrella Immunopharma, Inc. (NASDAQ: ESLA), focusing on its enterprise value to revenue forward. It appears to be a stub or a data-focused page from TradingView, offering an overview of the company's financials within the biotechnol
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jul 2026 17:11
- Source
- TradingView
GlobeNewswire
Direct company coverage
ESLA: Abbott Cooper PLLC Announces Investigation on Behalf of Estrella Immunopharma, Inc. Stockholders
Abbott Cooper PLLC has initiated an investigation into Estrella Immunopharma, Inc. (ESLA) to determine if its board of directors breached fiduciary duties or committed other wrongdoing. The firm is inviting stockholders to contact them to learn more about their legal rights, oper
- Tone
- Negative 29/100
- Event
- Regulatory and legal
- Published
- 09 Jul 2026 14:11
- Source
- GlobeNewswire
TradingView
Direct company coverage
Price to sales forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA
This article provides a brief financial overview for Estrella Immunopharma, Inc. (NASDAQ: ESLA), specifically focusing on its forward price-to-sales ratio. It presents the company's stock information, market status, and links to various financial data on TradingView, while emphas
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 11:40
- Source
- TradingView
Pluang
Direct company coverage
Investigation launched into Estrella Immunopharma's board for possible fiduciary breaches
Abbott Cooper PLLC has initiated an investigation into Estrella Immunopharma, Inc.'s board of directors to determine if they violated fiduciary duties or engaged in wrongdoing. The investigation, which could lead to legal action, aims to protect stockholder interests given that E
- Tone
- Negative 15/100
- Event
- Regulatory and legal
- Published
- 09 Jul 2026 02:40
- Source
- Pluang
TradingView
Direct company coverage
Price to earnings forward of Estrella Immunopharma, Inc. – BOATS:ESLAW
This article provides financial information for Estrella Immunopharma, Inc. (ESLAW) on TradingView, specifically focusing on its forward price-to-earnings ratio. It indicates that no trades have occurred and presents an overview of the company's financial data on the platform. Th
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 Jul 2026 00:10
- Source
- TradingView
Minichart
Direct company coverage
Estrella Immunopharma, Inc. (ESLA) 8-K Filing: Shareholder Vote Results & Company Details – June 2026
Estrella Immunopharma, Inc. announced the results of its Combined 2025/2026 Annual Meeting of Stockholders held on June 29, 2026. The meeting saw strong shareholder engagement with 70.5% of outstanding shares represented, confirming a quorum. While the specific proposal details w
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Jun 2026 22:25
- Source
- Minichart
Stock Titan
Direct company coverage
Estrella Immunopharma (ESLA) investors back 2026 auditor at virtual annual meeting
Estrella Immunopharma, Inc. (ESLA) stockholders ratified the appointment of Macias Gini & O’Connell LLP as their independent registered public accounting firm for the fiscal year ending December 31, 2026, during a virtual annual meeting on June 29, 2026. A substantial quorum was
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 21:10
- Source
- Stock Titan
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Estrella Immunopharma, Inc. – BOATS:ESLAW
This article provides financial information for Estrella Immunopharma, Inc. (ESLAW), specifically focusing on its enterprise value to EBITDA forward metric. The content indicates that the market is closed, with no trades observed, and presents this data as part of TradingView's f
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 20:10
- Source
- TradingView
TradingView
Direct company coverage
Estrella Immunopharma, Inc. Actuals & Estimates (NASDAQ:ESLA)
This article provides an overview of Estrella Immunopharma, Inc. (ESLA) stock performance, including current trading price, historical highs and lows, and analyst forecasts. It details financial actuals and estimates for the company, covering income statements, balance sheets, an
- Tone
- Negative 39/100
- Event
- Analyst action
- Published
- 25 Jun 2026 20:09
- Source
- TradingView
TradingKey
Direct company coverage
Estrella Immunopharma Inc (ESLA) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Estrella Immunopharma Inc (ESLA), detailing its previous and expected future EPS. While the company's financial health, valuation, price momentum, and institutional confidence usually involve comprehensive data, relevant information
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Jun 2026 19:42
- Source
- TradingKey
TradingKey
Direct company coverage
Estrella Immunopharma Inc (ESLA) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Estrella Immunopharma Inc (ESLA), detailing various volatility and risk metrics. It includes data points such as Beta vs S&P 500 index, Maximum Drawdown, Realised Volatility, and Daily Upside/Downside Volatility over different periods.
- Tone
- Negative 35/100
- Event
- Market update
- Published
- 21 Jun 2026 19:39
- Source
- TradingKey
TradingKey
Direct company coverage
Estrella Immunopharma Inc (ESLA) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of Estrella Immunopharma Inc (ESLA) through the lens of TradingKey. It highlights that critical financial data necessary to assess profitability, balance sheet, operational efficiency, growth potential, and shareholder returns hav
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 21 Jun 2026 19:10
- Source
- TradingKey
TradingKey
Direct company coverage
Estrella Immunopharma Inc (ESLA) Institutional Confidence
This article from TradingKey provides an overview of Estrella Immunopharma Inc (ESLA)'s institutional confidence. It details the institutional shareholding and shareholder activity, listing major holders like Eureka Therapeutics Inc, Renaissance Technologies LLC, Geode Capital Ma
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jun 2026 18:10
- Source
- TradingKey
TradingKey
Direct company coverage
Estrella Immunopharma Inc (ESLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Estrella Immunopharma Inc (ESLA), detailing its support, resistance, indicators, and moving averages. According to the analysis, various technical indicators and moving averages suggest a "Sell" signal for the stock, with 0 buy signal
- Tone
- Negative 19/100
- Event
- Market update
- Published
- 21 Jun 2026 17:10
- Source
- TradingKey
TradingKey
Direct company coverage
Estrella Immunopharma Inc (ESLA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Estrella Immunopharma Inc (ESLA), noting that key financial ratios such as P/E, P/B, P/S, and P/CF are not yet disclosed by the company. It displays the current stock price, market capitalization, and indicates that the data is delay
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jun 2026 17:09
- Source
- TradingKey
TradingKey
Direct company coverage
Estrella Immunopharma Inc (ESLAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey
This article provides an overview of Estrella Immunopharma Inc (ESLAW), focusing on its revenue breakdown and company profile. It notes that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page a
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 11:41
- Source
- TradingKey
TradingKey
Direct company coverage
Estrella Immunopharma Inc (ESLAW) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Estrella Immunopharma Inc (ESLAW), focusing on institutional holdings and major shareholders. It provides a quarterly breakdown of institutional share ownership and lists active institutional investors with their respective shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 11:41
- Source
- TradingKey
TradingKey
Direct company coverage
Estrella Immunopharma Inc (ESLAW) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Estrella Immunopharma Inc (ESLAW) focusing on its dividend and stock split history. It notes that the company has distributed $0.00 USD in dividends over the past five years and shows no data for past stock splits. The piece is primarily a dat
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 18 Jun 2026 11:41
- Source
- TradingKey
TradingKey
Direct company coverage
Estrella Immunopharma Inc (ESLA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Estrella Immunopharma Inc's (ESLA) dividend history and stock split information. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split events. The page also displays current stock
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 18 Jun 2026 02:40
- Source
- TradingKey
TradingKey
Direct company coverage
Estrella Immunopharma Inc (ESLAW) Institutional Confidence
This article provides details on the institutional confidence score for Estrella Immunopharma Inc (ESLAW), along with its stock performance data. It lists several institutional shareholders and their shareholdings or changes in holdings, highlighting notable movements such as red
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 02:40
- Source
- TradingKey
TradingKey
Direct company coverage
Estrella Immunopharma Inc (ESLAW) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Estrella Immunopharma Inc (ESLAW), stating that relevant data for EPS, Revenue, and Net Profit forecasts have not yet been disclosed by the company. It notes the stock's current trading price and highlights the absence of key financi
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 02:40
- Source
- TradingKey
StocksToTrade
Direct company coverage
Estrella Immunopharma Inc. (ESLA) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Estrella Immunopharma Inc. (ESLA) stock. As of the data provided, ESLA is trading at $1.06, down $0.02 (-1.85%). The article notes that there are no analyst ratings or earning information currently available for the company.
- Tone
- Negative 40/100
- Event
- Analyst action
- Published
- 13 Jun 2026 16:09
- Source
- StocksToTrade
Stock Titan
Direct company coverage
Estrella Immunopharma (ESLA) sets virtual 2026 meeting to ratify auditor
Estrella Immunopharma, Inc. (ESLA) will hold a virtual Combined 2025/2026 Annual Meeting of Stockholders on June 29, 2026, to ratify the appointment of Macias Gini & O’Connell LLP as their independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 21:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Estrella CEO and CFO head to Plaza Hotel for investor meetings
Estrella Immunopharma, a clinical-stage biopharmaceutical company, announced that its CEO and CFO will attend the D. Boral Capital 2026 Global Conference at The Plaza Hotel. They will be participating in one-on-one investor meetings to discuss the company's CD19 and CD22-targeted
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 24 May 2026 08:10
- Source
- Stock Titan
TradingView
Direct company coverage
Estrella Immunopharma, Inc. 1Q 2026: Net income $(2.29M), EPS $(0.05) — 10-Q Summary
Estrella Immunopharma, Inc. (ESLA) reported a net loss of $(2.29M) and a diluted loss per share of $(0.05) for the first quarter of 2026. This compares to a net loss of $(2.10M) and a diluted loss per share of $(0.06) in the same quarter last year. Key business highlights include
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 May 2026 10:39
- Source
- TradingView